Our investigation found that some of the changes in differentially expressed genes involved with hepatic steatosis, such as the farnesyl X receptor (FXR) and PNPLA3, were only altered by proglumide and not by genetic knockout of the CCK-BR. This evidence concerns the gene CCKBR and fatty liver disease.